Educational Disclaimer: This case study is for educational and informational purposes only. It does not constitute medical advice, clinical guidance, or a substitute for professional psychiatric evaluation. All diagnostic criteria referenced are from the DSM-5-TR (APA, 2022). Clinicians should rely on their professional training, direct patient assessment, and current evidence-based guidelines when making diagnostic and treatment decisions.

Clinical Vignette

Patient: "Mr. W," 72-year-old retired engineer, brought by his wife who describes fluctuating cognition, vivid visual hallucinations, and acting out his dreams.

Chief Concern: Wife: "Some days he's almost normal — sharp, conversational. Other days he stares past me like he doesn't know where he is. He sees children playing in the living room who aren't there. He punches and kicks in his sleep so violently I moved to a separate bedroom."

History of Present Illness: Mr. W's wife reports a 12-month progression of cognitive and behavioral changes. Key features: (1) Fluctuating cognition: marked day-to-day variation. 'Good days' where he converses normally and completes tasks. 'Bad days' where he is confused, stares blankly, and is unresponsive to questions. Fluctuations occur within the same day. (2) Visual hallucinations: sees children playing, animals in the house, and a 'man standing in the corner.' Hallucinations are vivid, detailed, and formed (not vague shapes). He can describe the children's clothing and the animals' breeds. Occur 3-4 times weekly. He retains partial insight (sometimes recognizes they are 'not really there'). (3) REM sleep behavior disorder (RBD): for the past 2 years (PREDATING cognitive symptoms by ~1 year), he has been physically acting out dreams — punching, kicking, yelling during sleep. His wife was injured once. (4) Parkinsonism: developed mild shuffling gait, reduced arm swing, and facial masking over the past 6 months. No resting tremor. (5) Cognitive domains: attention/executive function most impaired (fluctuating attention, difficulty with planning). Memory relatively preserved early (better than typical Alzheimer's).

Medical History: No prior neurological diagnosis. RBD for 2 years. No neuroleptic exposure.

Mental Status Exam: Alert but with variable attention (during interview, had 2 episodes of 'blanking out' for 15-20 seconds before reengaging). Speech slightly hypophonic. Facial expression reduced (masked facies). Mild cogwheel rigidity in right arm. Shuffling gait. MMSE 22/30 (attention and visuospatial items most impaired). Trail Making B: severely impaired (executive dysfunction). Delayed recall: 2/3 (relatively preserved for NCD). During exam, reported seeing 'a cat on the desk' (no cat present) — detailed, formed visual hallucination.

Step 1: Major NCD DSM-5-TR Criteria + Lewy Body Etiology

Major NCD Criteria met:

Significant cognitive decline (fluctuating attention, executive dysfunction, visuospatial impairment). Loss of functional independence (wife manages finances, supervises activities). Not during delirium. Not better explained by another mental disorder. MET — MAJOR NCD CONFIRMED.

Core Feature 1: Fluctuating cognition with pronounced variations in attention and alertness.

'Good days' vs. 'bad days.' Within-day fluctuation. Episodes of staring blankly (2 during exam). Variable attention confirmed on testing. PRESENT.

Core Feature 2: Recurrent visual hallucinations that are typically well formed and detailed.

Children, animals, man in corner. Detailed (describes clothing, breeds). Formed (not vague shapes). 3-4x weekly. PRESENT.

Core Feature 3: REM sleep behavior disorder (RBD).

2-year history of physically acting out dreams. PREDATED cognitive symptoms by 1 year. Wife injured. Classic RBD pattern. PRESENT.

Core Feature 4: Spontaneous parkinsonism (without neuroleptic exposure).

Shuffling gait, reduced arm swing, masked facies, cogwheel rigidity. Developed 6 months into cognitive decline. No neuroleptic exposure. PRESENT.

Classification: ALL 4 core features present → PROBABLE Lewy Body Disease.

2 core features = probable. Mr. W has all 4. PROBABLE DLB — HIGHEST CERTAINTY.

Step 2: DLB vs. Alzheimer's vs. Parkinson's Disease Dementia

Feature DLB Alzheimer's PDD This Patient
Cognition pattern FLUCTUATING (variable day-to-day) Steadily declining Develops after established PD DLB: fluctuating
Most impaired domain Attention/executive Memory (learning/recall) Attention/executive Attention/executive
Memory early Relatively preserved MOST impaired early Variable Relatively preserved (2/3 recall)
Visual hallucinations Early and prominent (core feature) Late if present Present but after PD onset Early and prominent
RBD Often precedes cognitive symptoms Uncommon Present Preceded cognition by 1 year
Parkinsonism timing Within 1 year of cognitive onset Uncommon YEARS before cognitive decline Within 6 months of cognitive onset (DLB 1-year rule)

Critical Safety Warning

DLB patients are SEVERELY sensitive to neuroleptic (antipsychotic) medications. Traditional antipsychotics can cause life-threatening neuroleptic sensitivity reactions (severe rigidity, altered consciousness, autonomic instability) in DLB. If hallucinations require pharmacological treatment, pimavanserin or low-dose quetiapine are preferred.

Diagnostic Formulation

Diagnostic Conclusion

Major Neurocognitive Disorder with Probable Lewy Bodies (G31.83 + F02.80): Major NCD criteria met. All 4 core DLB features present (fluctuating cognition, visual hallucinations, RBD, parkinsonism). Classification: probable DLB (highest certainty). RBD preceded cognitive symptoms by 1 year (common in DLB). Treatment: cholinesterase inhibitor (rivastigmine has specific evidence for DLB). CRITICAL: avoid ALL traditional antipsychotics (neuroleptic sensitivity). For hallucinations: pimavanserin or low-dose quetiapine only if hallucinations cause distress. Melatonin or clonazepam for RBD. Physical therapy for parkinsonism.

Teaching Points

  • The '1-year rule' distinguishes DLB from Parkinson's Disease Dementia (PDD): if cognitive symptoms develop within 1 year of parkinsonism (or before), the diagnosis is DLB. If cognitive symptoms develop more than 1 year after established Parkinson's disease motor symptoms, the diagnosis is PDD. The underlying pathology (Lewy bodies) is the same; the distinction is clinical and reflects different patterns of disease spread.
  • Neuroleptic sensitivity is a CARDINAL safety concern in DLB. Traditional antipsychotics (haloperidol, chlorpromazine) and even some atypical antipsychotics can cause severe, potentially fatal reactions in DLB patients. If antipsychotic treatment is necessary, pimavanserin (selective 5-HT2A inverse agonist, FDA-approved for PD psychosis) or very low-dose quetiapine are the safest options.
  • REM sleep behavior disorder (RBD) frequently PRECEDES cognitive decline in DLB by years to decades. Isolated RBD (without other neurological symptoms) is now recognized as a prodromal phase of synucleinopathies (DLB, PDD, multiple system atrophy). Most individuals with idiopathic RBD will develop a synucleinopathy within 10-15 years.
  • Visual hallucinations in DLB are characteristically well-formed, detailed, and recurrent. Patients can describe specific people, animals, or scenes. This differs from the vague, shadow-like visual disturbances seen in some other conditions. Partial insight (knowing the hallucinations are not real) is common early in DLB.
  • Cholinesterase inhibitors (particularly rivastigmine) show greater benefit in DLB than in Alzheimer's disease. This reflects the greater cholinergic deficit in DLB. Cholinesterase inhibitors can improve cognition, hallucinations, and behavioral symptoms in DLB.